Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01742832 · ClinicalTrials.gov registry record · Phase 2
Double-Blind Treatment of Major Depressive Disorder With Vilazodone
A Phase 2 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 2
- Development phase
- 79
- Enrollment target
NCT01742832 is a Phase 2 study that has completed, run by University of Chicago. The registered enrollment target is 79 participants.
The verdict
NCT01742832, a Phase 2 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 79 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of vilazodone for the treatment of major depressive disorder versus citalopram. Doctors want to determine if vilazodone is effective for the treatment of major depressive disorder in those who have not responded to generic selective serotonin reuptake inhibitors (SSRI), which is a class of anti-depressant drugs such as Prozac, Lexapro, Paxil, or Zoloft. Both vilazodone and citalopram have been approved for the treatment of major depressive disorder. This research is being done because the researchers want to find out if vilazodone works in reducing the symptoms of depression significantly more than a generic SSRI.
Interventions
- DRUG Citalopram
- DRUG Vilazodone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2013-05 |
| Est. Completion | 2016-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01742832
The ClinicalTrials.gov registry entry for NCT01742832 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Citalopram is the first listed.
NCT01742832 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01742832 about?
NCT01742832 is a clinical study titled "Double-Blind Treatment of Major Depressive Disorder With Vilazodone". The purpose of this study is to evaluate the safety and effectiveness of vilazodone for the treatment of major depressive disorder versus citalopram. Doctors want to determine if vilazodone is effective for the treatment of major depressive disorder in those who have not responded to generic selecti...
What is the current status of trial NCT01742832?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 79 participants. The study started on 2013-05. Estimated completion is 2016-03.
What interventions are being tested in trial NCT01742832?
The interventions under investigation include: Citalopram (DRUG), Vilazodone (DRUG).
Who is sponsoring clinical trial NCT01742832?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.